A pilot program with American Oncology Network allows clinicians to order molecular tests and receive results within their existing workflow.
Quest Diagnostics announced the integration of its Haystack MRD circulating-tumor DNA (ctDNA) test and genomic profiling services for solid tumor cancers within OncoEMR, an electronic health record (EHR) from Flatiron Health.
The integration is launching as part of a pilot program with American Oncology Network and other community oncology providers. Quest Diagnostics is the largest clinical reference lab to integrate oncology tests in the platform using the Molecular Profiling Integration (MPI) ordering feature, which is designed to support the specialized ordering requirements of molecular tests.
Once the full rollout is finished, the integration will allow 4,700 clinicians across 1,600 community-based cancer care locations in the United States to access these services.
“By integrating Quest’s advanced oncology services directly into existing workflows, we’re making it easier for physicians to access critical testing insights without adding complexity to their day. This collaboration helps reduce administrative burden so clinicians can spend less time navigating processes and more time focused on caring for patients with cancer,” says Quincy Weatherspoon, chief network officer, US point of care, Flatiron Health, in a release.
Molecular oncology testing often involves dozens or hundreds of individual genetic biomarkers, which can complicate ordering and results reporting, according to Quest Diagnostics. The use of the new ordering feature allows providers to set up accounts faster, order tests with fewer steps, and receive reports within their daily EHR workflows.
American Oncology Network, which includes more than 350 providers across 21 states, is a lead participant in the pilot. Nearly 200 of its sites currently have access to the ordering feature for Quest Diagnostics tests.
“At [American Oncology Network], our aim is to provide comprehensive support, ancillary services, and practice management benefits to help community physicians to make cancer care better. Empowering them to use OncoEMR MPI via Quest Diagnostics is an important step in that mission,” says Dr Brian Mulherin, medical director at American Oncology Network, in a release. “Under this arrangement, our rapidly growing network of physicians can quickly and easily order Quest’s innovative cancer tests, such as Haystack MRD, to help guide patient care.”
The Haystack MRD test is a ctDNA minimal residual disease test for solid tumor cancers. The company also offers genomic profiling panels that use sequencing to identify up to 530 genes associated with therapy response.
“At Quest Diagnostics, we strive to provide comprehensive cancer services that empower providers to work with patients to make optimal care decisions,” says Asia Chang, vice president and general manager, oncology at Quest Diagnostics, in a release. “We’re looking forward to providing oncologists at AON and other organizations a single-source ordering and results solution via OncoEMR MPI, as well as the world-class expertise they’ve come to expect from Quest.”
Quest Diagnostics plans to launch the full integration to providers nationwide in the second half of 2026. The company also provides specialized tests through the Epic Aura platform.
Photo caption: Haystack MRD test
File photo/Quest Diagnostics
